<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="much more rapidly, quickly causing many more total deaths than" exact="infection" post="with both previous coronaviruses combined. Currently, there are no"/>
 <result pre="to compare viral replication and immune activation caused by experimental" exact="infection" post="with SARS-CoV-2 to that for SARS-CoV [3]. This self-paired"/>
 <result pre="(types I and II pneumocytes, as well as alveolar macrophages)," exact="infection" post="and viral replication was much more efficient for SARS-CoV-2"/>
 <result pre="SARS-CoV-2 than SARS-CoV. The higher viral levels associated with SARS-CoV-2" exact="infection" post="may reflect an even more striking observation from this"/>
 <result pre="response and suppresses endogenous IFN production, these results suggest that" exact="treatment" post="with exogenous IFN to stimulate antiviral immunity might be"/>
 <result pre="are the first IFNs produced in response to influenza virus" exact="infection" post="and these cytokines act at the epithelial barrier to"/>
 <result pre="the virus to other mice much more efficiently [10]. Intranasal" exact="treatment" post="with recombinant IFN-Î» inhibits influenza virus replication, protects the"/>
 <result pre="especially true of coronaviruses. In a related previous study, experimental" exact="infection" post="with a MERS-CoV strain (human coronavirus EMC) failed to"/>
 <result pre="I and type III IFNs in respiratory tissue cultures, while" exact="infection" post="with influenza virus induced high levels of both IFN"/>
 <result pre="previous work from Professor Yuenâ€™s group, neither MERS-CoV nor SARS-CoV" exact="infection" post="induced significant expression of type I IFNs in human"/>
 <result pre="SARS-CoV-2. There are as yet no data with respect to" exact="treatment" post="of SARS-CoV-2 infection with IFN-Î»; however, there are relevant"/>
 <result pre="as yet no data with respect to treatment of SARS-CoV-2" exact="infection" post="with IFN-Î»; however, there are relevant data concerning SARS-CoV"/>
 <result pre="MERS-CoV [2]. In macaque monkeys experimentally infected with SARS-CoV, prophylactic" exact="treatment" post="with intramuscular pegylated IFN-Î± reduced viral replication and excretion,"/>
 <result pre="provide similar prophylactic protection against coronavirus infections. With respect to" exact="treatment" post="of established infection, in the aforementioned macaque model, animals"/>
 <result pre="prophylactically treated group and untreated controls [14]. Most studies of" exact="treatment" post="for severe MERS-CoV infection have not shown an association"/>
 <result pre="untreated controls [14]. Most studies of treatment for severe MERS-CoV" exact="infection" post="have not shown an association of IFN-Î± therapy with"/>
 <result pre="is that the time to administration is critical, and that" exact="treatment" post="with IFN-Î± may have been delivered too late to"/>
 <result pre="of MERS-CoV. Pegylated IFN-Î»1, an investigational agent that has undergone" exact="testing" post="in &amp;gt; 3000 human subjects, might be an effective"/>
 <result pre="in &amp;gt; 3000 human subjects, might be an effective early" exact="treatment" post="for SARS-CoV-2. In phase 2 and 3 clinical trials"/>
 <result pre="that proved to be even more effective. However, that extensive" exact="testing" post="of pegylated IFN-Î»1 established its safety, opening the door"/>
 <result pre="in other infections. Currently, pegylated IFN-Î»1 is being tested for" exact="treatment" post="of hepatitis D virus infection, including in a clinical"/>
 <result pre="an early and rapid response to attenuate disease and prevent" exact="infection" post="spread. As the pathogenesis of COVID-19 is incompletely understood,"/>
 <result pre="where pegylated IFN-Î»1 has been tested so far, and SARS-CoV-2" exact="infection" post="is that patients with severe COVID-19 have a high"/>
 <result pre="ideally, should be first studied in patients with early SARS-CoV-2" exact="infection" post="or as prophylaxis. Possible trials of pegylated IFN-Î»1 for"/>
 <result pre="et al.Interferon-Î» mediates non-redundant front-line antiviral protection against influenza virus" exact="infection" post="without compromising host fitness. Immunity2017; 46:875â€&quot;90.e6.28514692 10.KlinkhammerJ, SchnepfD, YeL,"/>
 <result pre="et al.Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus" exact="infection" post="in macaques. Nat Med2004; 10:290â€&quot;3.14981511 15.HammingOJ, TerczyÅ&quot;ska-DylaE, VieyresG, et"/>
 <result pre="GroupA randomized phase 2b study of peginterferon lambda-1a for the" exact="treatment" post="of chronic HCV infection. J Hepatol2014; 61:1238â€&quot;46.25064437 20.DickensheetsH, SheikhF,"/>
</results>
